Carteolol (patient information): Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
'''''For patient information about Carteolol, click [[Carteolol (patient information)|here]]''''' | '''''For patient information about Carteolol, click [[Carteolol (patient information)|here]]''''' | ||
{{SB}} | {{SB}} OCUPRESS<sup>®</sup> | ||
==Overview== | ==Overview== | ||
Revision as of 06:07, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Carteolol, click here
Synonyms / Brand Names: OCUPRESS®
Overview
Category
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages